Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564
Alone and in Combination with Pembrolizumab in Subjects with
Advanced Solid Tumors
The University of Virginia is conducting a clinical research study for adults ages 18 and over, who have advanced solid tumors. The purpose of this clinical research study is to learn more about the safety of an investigational drug, AMV564, and to learn how AMV564 affects your cancer-specific cells and other blood cells.
The treatment period is estimated to last approximately 3 months, but this can differ depending on how you react to the drug. The sub sequential follow-up period will involve a monthly check in for 6 month and then every 3 months thereafter. The study is expected to last 36 months total.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to your or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT04128423
Compensation: $50 per completed visit; Reimbursement: Up to $175 per night for hotel